Effects of interferon-α-2a on Th3 cytokine response in multiple myeloma patients

Tumori

Volumn 90, Issue 4, 2004, Pages 387-389

  Sonmez, Mehmet ^a   Sonmez, Bircan ^b   Eren, Necmi ^a   Yilmaz, Mustafa ^a   Karti, S Sami ^a   Ovali, Ercument ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b Department of Nuclear Medicine   (Turkey)

Author keywords

Cytokines; IFN 2a; Multiple myeloma

Indexed keywords

ALPHA2A INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TH3 CYTOKINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MALE; MULTIPLE MYELOMA; SERUM; TUMOR IMMUNITY;

EID: 4644229866     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000404     Document Type: Article

References (25)

1. Barlogie B, Shaughnessy J, Munshi N, Epstein J: Plasma cell myeloma. In: William's hematology, Beutler E, Lichtman M, Coller B, Kipps T, Seligsohn U (Eds), 6th edn, pp 1279-1034, McGraw-Hill, New York, 2001.
2. Lappin MB, Campbell JD: The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy. Blood Rev, 14: 228-239, 2000.
3. Bartnes K, Hannestad K: Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigen-presenting cells. Immunology, 99: 510-522, 2000.
4. Cook G, Campbell JD: Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev, 13: 151-162, 1999.
5. Frassanito MA, Cusmai A, Dammacco F: Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol, 125: 190-197, 2001.
6. Raitakari M, Brown RD, Gibson J, Joshua DE: T cells in myeloma. Hematol Oncol, 21: 33-42, 2003.
7. Treon SP, Raje N, Anderson KC: Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol, 27: 598-613, 2000.
8. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q: Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood, 99: 3280-3285, 2002.
9. Schmidt-Wolf GD, Schmidt-Wolf IG: Immunomodulatory gene therapy for haematological malignancies. Br J Haematol, 117: 23-32, 2002.
10. Ludwig H, Fritz E: Maintenance with Interferon alpha in myeloma. In: Acute leukemias VII, Hiddemann et al (Eds), pp 1185-1192, Springer-Verlag, Berlin, Heidelberg, 1998.
11. Grander D: How does interferon-alpha exert its antitumour activity in multiple myeloma? Acta Oncol, 39: 801-805, 2000.
12. Matsui W, Huff CA, Vala M, Barber J, Smith BD, Jones RJ: Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation. Br J Haematol, 121: 251-258, 2003.
13. Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, Almasan A: Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood, 98: 2183-2192, 2001.
14. Motta MR, Castellani S, Rizzi S, Curti A, Gubinelli F, Fogli M, Ferri E, Cellini C, Baccarani M, Lemoli RM: Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol, 121: 240-250, 2003.
15. Durie BMG, Salmon SE: Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Recent Advances in Heamatology, Hoffbrand AV, Brain MC, Hirsh J (Eds), pp 243-261, Churchill Livingstone, New York, 1977.
16. Durie BMG, Salmon SE: A clinical staging system for multiple myeloma. Cancer, 36: 842-854, 1975.
17. Maeda H, Shiraishi A: TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol, 156: 73-78, 1996.
18. Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM: Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol, 66: 981-988, 1999.
19. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP: Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood, 77: 587-593, 1991.
20. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF: Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia, 10: 866-876, 1996.
21. Cimino G, Avvisati G, Amadori S, Cava MC, Giannarelli D, Di Nucci GD, Magliocca V, Petrucci MT, Poti G, Sgadari C: High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br J Haematol, 75: 373-377, 1990.
22. Stritzke J, Zunkel T, Steinmann J, Schmitz N, Uharek L, Zeis M: Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. Br J Haematol, 120: 27-35, 2003.
23. Millar BC, Millar JL, Powles RL, Catovsky D: Interferon-gamma+ and interleukin-2+ T cells in peripheral blood from multiple myeloma patients in relation to disease status and maintenance therapy with interferon-alpha-2b (intron A). Br J Haematol, 98: 119-125, 1997.
24. Porrata LF, Inwards DJ, Lacy MQ, Markovic SN: Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation. Bone Marrow Transplant, 28: 673-680, 2001.
25. Lauta VM: A review of the cytokine network in multiple myeloma. Cancer, 15: 2440-2452, 2003.